Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Wilhelm

Urology Amarillo, TX Medical Doctor

NPI 1326039959 CMS profile 104736

1900 Medi Park Dr, Amarillo, TX 79106

Open in the dashboard

General payments

$5,621

263 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$23,000 paid to institutions, not to them · program year 2025

Through program year 2025, David Wilhelm of Amarillo, TX is reported in the CMS Open Payments database as having received $5,621 across 263 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $23,000 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 68th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,076 44
2024 General $624 26
2023 General $911 35
2022 General $895 42
2021 General $646 37
2020 General $546 32
2019 General $923 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Wilhelm
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to David Wilhelm were reported at $1,076. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year David Wilhelm Urology median Middle half National median
2019 $923 $480 $147–$1,201 $163
2020 $546 $246 $87–$645 $114
2021 $646 $358 $111–$1,000 $132
2022 $895 $476 $143–$1,263 $149
2023 $911 $560 $168–$1,461 $160
2024 $624 $563 $170–$1,464 $164
2025 $1,076 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Astellas Pharma US Inc $1,184 73 payments
  2. Pfizer Inc. $574 29 payments
  3. Dendreon Pharmaceuticals LLC $550 22 payments
  4. AbbVie, Inc. $482 23 payments
  5. Boston Scientific Corporation $390 7 payments
  6. Sumitomo Pharma America, Inc. $340 19 payments
  7. Urogen Pharma, Inc. $266 11 payments
  8. Janssen Biotech, Inc. $224 10 payments
  9. Myriad Genetic Laboratories, Inc. $217 6 payments
  10. PROCEPT BioRobotics Corporation $175 2 payments
  11. Other $1,219 61 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,472 260 payments
  2. Education $149 3 payments
Products named General payments · program years 2019–2025
  1. XTANDI $1,272 73 payments
  2. MYRBETRIQ $785 53 payments
  3. PROVENGE $550 22 payments
  4. GEMTESA $401 23 payments
  5. ORGOVYX $393 23 payments
  6. LUPRON DEPOT $319 15 payments
  7. JELMYTO $227 9 payments
  8. ERLEADA $224 10 payments
  9. TALZENNA $194 10 payments
  10. SpaceOAR VUE System - 10mL $184 2 payments
  11. Other $2,009 90 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,954

Median for Urology: 1,053

Drug cost

$4,193,894

Median for Urology: $101,464

Branded share of claims

32.9%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtandi Enzalutamide Brand 251 $3,037,359
Erleada Apalutamide Brand 29 $420,388
Talzenna Talazoparib Tosylate Brand 20 $356,070
Abiraterone Acetate Generic 120 $138,779
Orgovyx Relugolix Brand 47 $126,036
Myrbetriq Mirabegron Brand 150 $80,381
Mirabegron Er Mirabegron Brand 23 $11,730
Tamsulosin Hcl Generic 538 $7,200
Finasteride Generic 266 $3,329
Testosterone Generic 23 $2,087

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 110 billing codes

Paid by Medicare

$349,206

Of which drugs: $132,324

Medicare patients

1,005

Average age 75

Services billed

15,904

107 women, 898 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 53%
Arthritis 48%
Ischemic heart disease 36%
Diabetes 28%
Chronic kidney disease 25%
Atrial fibrillation 18%
Heart failure 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 15 3,420 $70,886
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 53 429 $59,397
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 66 6,701 $659

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $91
$91 — —
XTANDI
  • PFIZER INC. $46
$46 251 —
ORGOVYX
  • PFIZER INC. $46
$46 47 —
JELMYTO
  • UROGEN PHARMA, INC. $45
$45 — —
TALZENNA
  • PFIZER INC. $39
$39 20 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

263 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record